<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116010</url>
  </required_header>
  <id_info>
    <org_study_id>PHAGOBURN</org_study_id>
    <nct_id>NCT02116010</nct_id>
  </id_info>
  <brief_title>Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients</brief_title>
  <acronym>PHAGOBURN</acronym>
  <official_title>Phase I/II Clinical Trial Randomized, Multicentric, Open Label, Standard of Care (Silver Sulfadiazine) Controlled Aiming at Assessing Tolerance and Efficacy of Local Bacteriophage Treatment of Wound Infections Due to E. Coli or P. Aeruginosa in Burned Patients Using Pherecydes Pharma Anti-Escherichia Coli and Anti-Pseudomonas Aeruginosa Bacteriophages GMP Produced Cocktails . This Project is a European Research &amp; Development (R&amp;D) Project Funded by the European Commission Under the 7th Framework Programme for Research and Development Involving 7 Clinical Sites in EU.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pherecydes Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pherecydes Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of PHAGOBURN is to assess tolerance and efficacy of local bacteriophage
      treatment of E. coli or P. aeruginosa wound infections in burned patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PHAGOBURN is a Phase I/II clinical trial randomized, multicentric, open label, standard of
      care (Silver Sulfadiazine) controlled aiming at assessing tolerance and efficacy of local
      bacteriophage treatment of wound infections due to E. coli or P. aeruginosa in burned
      patients using Pherecydes Pharma anti-Escherichia coli and anti-Pseudomonas aeruginosa
      bacteriophage cocktails GMP produced. This project is a European Research &amp; Development (R&amp;D)
      project funded by the European Commission under the 7th Framework Programme for Research and
      Development. This project is involving 7 clinical sites in EU.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for bacteria reduction adjusted on antibiotic treatment</measure>
    <time_frame>7 days</time_frame>
    <description>Time necessary for a persistent bacteria reduction of two modes or persistent bacteria eradication relative to D0 adjusted on antibiotic treatment (active on targeted strain) introduced between D1 to D7. Bacteria count performed on bacteria targeted by the phages cocktail collected from surface swab samples assessed by the microbiologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerance of treatment</measure>
    <time_frame>21 days</time_frame>
    <description>Adverse events frequencies will be assessed in each treatment arms. Phages therapy safety profile will be compared to safety profile of standard of care .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence an delay of infection reduction with different bacterial species from the targets</measure>
    <time_frame>7 days</time_frame>
    <description>The criteria will be assessed according to wound clinical examination and bacteria count by the microbiologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of sites cured</measure>
    <time_frame>7 days</time_frame>
    <description>The number of infected burns or infected wounds getting a clinical improvement will be described and compared between treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>E. coli, Standard of care : Silver Sulfadiazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E. coli, Phages cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P. aeruginosa, Standard of care : Silver Sulfadiazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P. aeruginosa, Phages cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E. coli Phages cocktail</intervention_name>
    <description>Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection</description>
    <arm_group_label>E. coli, Phages cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care : Silver Sulfadiazine</intervention_name>
    <description>Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound</description>
    <arm_group_label>E. coli, Standard of care : Silver Sulfadiazine</arm_group_label>
    <arm_group_label>P. aeruginosa, Standard of care : Silver Sulfadiazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P. Aeruginosa, Phages cocktail</intervention_name>
    <description>Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection</description>
    <arm_group_label>P. aeruginosa, Phages cocktail</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman

          -  Adult Informed consent obtained from patient or next of kin

          -  In-hospital patient treated for burn wounds in a burn unit

          -  Burn wound (grafted or not) or graft harvesting area, presenting local signs of
             infection defined by SFETB criteria:

               -  A local or loco-regional inflammatory reaction;

               -  And/or an adverse and unexpected local evolution;

               -  And/or regarding burn wounds: presence of pus, fast spontaneous debridement and
                  separation, occurrence of blackish spots (necrosis or haemorrhage), unexplained
                  conversion from a superficial lesion to a deep one (&gt; 48th hour);

               -  And/or regarding graft donor sites: presence of pus, unexplained delay in
                  epidermisation, bedsore;

               -  And/or regarding graft recipient sites: presence of pus, lysis of grafts,
                  necrosis of fat located under the graft.

          -  Burn wounds with a microbiologically documented infection, as defined by positive
             surface swab, due to Escherichia coli or Pseudomonas aeruginosa whatever their
             resistance profile

          -  Treated by povidone-iodine

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman

          -  Intercurrent condition requiring a treatment which may interfere with analysis
             results: such as high dose of chronic corticotherapy, immunosuppressive medication,
             oncologic chemotherapy

          -  Patient included in an interventional research protocol with therapeutic intervention
             still ongoing upon inclusion time or having participated into anti-infective drug
             trials during the previous month.

          -  Patient considered as part of a vulnerable population

          -  Patient for whom treatment limitation or withdrawal during study period is considered

          -  Allergy to Silver Sulfadiazine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Jault, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Santé des Armées, Hopital Percy (Clamart, France)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Jault, MD</last_name>
    <phone>+33 1 41 46 62 13</phone>
    <email>patrick.jault@santarm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Cotton</last_name>
    <phone>+335 61 00 13 55</phone>
    <email>christine.cotton@statitec.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Militaire Reine Astrid</name>
      <address>
        <city>Brussel</city>
        <zip>B-1120</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Paul Pirnay, PhD</last_name>
      <phone>+32 2 264 4844</phone>
      <email>jean-paul.pirnay@mil.be</email>
    </contact>
    <investigator>
      <last_name>Serge Jennes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Françoise Rousseau, MD</last_name>
      <phone>+32 4 3667495</phone>
      <email>afrousseau@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Anne-Françoise Rousseau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'instruction des armées Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Jault, MD</last_name>
      <phone>+33 (0)1 41 46 62 13</phone>
      <email>patrick.jault@santarm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Leclerc, MD</last_name>
      <phone>+33 (0)1 41 46 62 13</phone>
      <email>thomas.leclerc@m4x.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Jault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Leclerc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier ST Joseph et St Luc</name>
      <address>
        <city>Lyon</city>
        <zip>F-69365</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Ravat, MD</last_name>
      <phone>+33 (0) 478 618 925</phone>
      <email>fravat@ch-stjoseph-stluc-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>François Ravat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grégory Resch, PhD</last_name>
      <phone>+41 21 692 56 23</phone>
      <email>gregory.resch@unil.ch</email>
    </contact>
    <investigator>
      <last_name>Yok-Ai Que, Mer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wound Infection in burned patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfadiazine</mesh_term>
    <mesh_term>Silver Sulfadiazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

